BR112012013581A8 - vacinas de malária baseadas em ferlinas apicomplexas, proteínas semelhantes a ferlinas e outras proteínas que contêm o domínio c2 - Google Patents

vacinas de malária baseadas em ferlinas apicomplexas, proteínas semelhantes a ferlinas e outras proteínas que contêm o domínio c2

Info

Publication number
BR112012013581A8
BR112012013581A8 BR112012013581A BR112012013581A BR112012013581A8 BR 112012013581 A8 BR112012013581 A8 BR 112012013581A8 BR 112012013581 A BR112012013581 A BR 112012013581A BR 112012013581 A BR112012013581 A BR 112012013581A BR 112012013581 A8 BR112012013581 A8 BR 112012013581A8
Authority
BR
Brazil
Prior art keywords
ferline
proteins
apicomplex
domain
malaria vaccines
Prior art date
Application number
BR112012013581A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012013581A2 (pt
Inventor
Mueller Ann-Kristin
Morath Eva
Original Assignee
Univ Heidelberg Ruprecht Karls
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Heidelberg Ruprecht Karls filed Critical Univ Heidelberg Ruprecht Karls
Publication of BR112012013581A2 publication Critical patent/BR112012013581A2/pt
Publication of BR112012013581A8 publication Critical patent/BR112012013581A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012013581A 2009-12-05 2010-12-06 vacinas de malária baseadas em ferlinas apicomplexas, proteínas semelhantes a ferlinas e outras proteínas que contêm o domínio c2 BR112012013581A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26702609P 2009-12-05 2009-12-05
PCT/EP2010/007399 WO2011066995A1 (en) 2009-12-05 2010-12-06 Malaria vaccines based on apicomplexan ferlins, ferlin-like proteins and other c2-domain containing proteins

Publications (2)

Publication Number Publication Date
BR112012013581A2 BR112012013581A2 (pt) 2017-01-10
BR112012013581A8 true BR112012013581A8 (pt) 2017-12-26

Family

ID=43499977

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012013581A BR112012013581A8 (pt) 2009-12-05 2010-12-06 vacinas de malária baseadas em ferlinas apicomplexas, proteínas semelhantes a ferlinas e outras proteínas que contêm o domínio c2

Country Status (8)

Country Link
US (1) US8968750B2 (https=)
EP (1) EP2507259B1 (https=)
JP (1) JP2013512866A (https=)
CN (1) CN102781958B (https=)
BR (1) BR112012013581A8 (https=)
CA (1) CA2783107C (https=)
MX (1) MX2012006458A (https=)
WO (1) WO2011066995A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103491979B (zh) 2010-12-06 2016-12-21 马尔瓦有限责任公司 基于来自恶性疟原虫的红细胞前期抗原的疟疾疫苗
AU2014203873A1 (en) * 2013-01-07 2015-07-30 Biomedical Research Models, Inc. Therapeutic vaccines for treating herpes simplex virus type 2 infections
AU2015305754B2 (en) 2014-08-19 2018-10-25 Merck Sharp & Dohme Llc Anti-tigit antibodies
EP3334757A4 (en) * 2015-08-14 2019-04-03 Merck Sharp & Dohme Corp. ANTI-Tigit ANTIBODY
JP2017210441A (ja) * 2016-05-26 2017-11-30 国立大学法人大阪大学 マラリアワクチン

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518528A (en) * 1983-05-19 1985-05-21 Rasnick David W α Amino fluoro ketones
US5198334A (en) * 1989-07-21 1993-03-30 Terumo Corporation Protection of natural killer cell cytolytic activity in peripheral blood mononuclear cells
GB9406492D0 (en) * 1994-03-31 1994-05-25 Isis Innovation Malaria peptides
US6669945B1 (en) * 1997-01-21 2003-12-30 New York University Universal T-cell epitopes for anti-malarial vaccines
US20030077653A1 (en) * 2000-04-20 2003-04-24 The University Of Georgia Research Foundation, Inc. Method for the identification of active site protease inactivators
US7811575B2 (en) * 2001-04-10 2010-10-12 Agensys, Inc. Nucleic acids and corresponding proteins entitled 158P3D2 useful in treatment and detection of cancer
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
CA2409897A1 (en) 2002-10-25 2004-04-25 Institut Pasteur Plasmodium falciparum virulence factor var o
US7198791B2 (en) 2003-03-03 2007-04-03 Pluschke, Gerd Et Al. Compositions and methods for the generation of protective immune responses against malaria
US8206725B2 (en) * 2003-08-26 2012-06-26 The Council Of The Queensland Institute Of Medical Research Immunogenic agent and pharmaceutical composition for use against homologous and heterologous pathogens including plasmodium SPP
WO2005063804A1 (en) 2003-12-30 2005-07-14 Københavns Universitet Panum Compounds useful in the diagnosis and treatment of malaria
US7951782B2 (en) * 2005-09-29 2011-05-31 Maruha Nichiro Seafoods, Inc Composition effective to prevent or treat adult disease
GB0601059D0 (en) * 2006-01-19 2006-03-01 Univ Durham Target
WO2009082440A2 (en) 2007-12-18 2009-07-02 Vaxinnate Corporation Compositions of toll-like receptor agonists and malaria antigens and methods of use
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) * 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US20110165649A1 (en) * 2010-01-06 2011-07-07 Brett Tyler Methods and compositions to improve the health of plants, animals and microbes by manipulating protein entry into symbionts and their hosts
CN103491979B (zh) * 2010-12-06 2016-12-21 马尔瓦有限责任公司 基于来自恶性疟原虫的红细胞前期抗原的疟疾疫苗

Also Published As

Publication number Publication date
US20120308598A1 (en) 2012-12-06
JP2013512866A (ja) 2013-04-18
EP2507259B1 (en) 2016-08-24
WO2011066995A1 (en) 2011-06-09
US8968750B2 (en) 2015-03-03
CA2783107C (en) 2018-08-07
EP2507259A1 (en) 2012-10-10
CN102781958A (zh) 2012-11-14
CN102781958B (zh) 2017-07-11
MX2012006458A (es) 2012-09-07
BR112012013581A2 (pt) 2017-01-10
CA2783107A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
CY1122898T1 (el) Απεκκριση πολυπεπτιδιων που περιεχουν αιμη
CY1121560T1 (el) Ανοσογονικη συνθεση
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
MX2022010324A (es) Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
WO2014152157A3 (en) Methods and compositions for the generation and use of conformation-specific antibodies
CL2016000344A1 (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
BR112016020065A2 (pt) sítios específicos para modificar anticorpos para fazer imunoconjugados
MX374291B (es) Modulocinas basadas en dominio sushi de interleucina-15 (il-15) y receptor alfa de interleucina-15 (il-15ra).
BRPI1013780A2 (pt) composições para imunização contra staphylococcus aureus.
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
CO6680688A2 (es) Anticuerpos para el receptor del factor de crecimiento epidérmico 3(her3)
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
BR112018077188A2 (pt) frutose-6-fosfato-3-epimerase termoestável inovadora e um método para produzir alulose com o uso da mesma
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
CL2020000897A1 (es) Composición de proteínas de guisante que tiene calidad nutricional mejorada.
BR112016024494A8 (pt) análogo de peptídeo e seu uso
CR20130632A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
BR112013007514A2 (pt) anticorpo isolado, uso da composição e método
BR112015018265A2 (pt) Composições nutricionais contendo um componente peptídico com propriedades estimulantes de adiponectina e utilizações das mesmas
BR112012013581A2 (pt) vacinas de malária baseadas em ferlinas apicomplexas, proteínas semelhante a ferlinas e outras proteínas que contêm o domínio c2
MX2019007252A (es) Metodos y composiciones para vacunas del virus del dengue.
MX2018003445A (es) Expresion de proteinas que contienen fc.
BR112013000840A2 (pt) método para aumentar o efeito de forma ativada potencializada de anticorpo para molécula endógena biológica, composição farmacêutica e uso de combinação de molécula biológica endógena com forma ativada potencializada de anticorpo para a sintase no endotelial.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements